Biotech Firms Announce Financial Results, Resignations, Reintroduce Treatments and Receive Reviews on Key Products - Research Report on Insmed, ImmunoGen, VIVUS, Theravance, and XOMA

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Sep 03, 2013, 08:00 ET

NEW YORK, September 3, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Insmed Incorporated (NASDAQ: INSM), ImmunoGen, Inc. (NASDAQ: IMGN), VIVUS, Inc. (NASDAQ: VVUS), Theravance, Inc. (NASDAQ: THRX), and XOMA Corporation (NASDAQ: XOMA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Insmed Incorporated Research Report

On August 6, 2013, Insmed Incorporated (Insmed) reported its Q2 2013 financial results. In Q2 2013, the Company reported a net loss of $8.9 million, or $0.28 per share, compared with a net loss of $9.7 million, or $0.39 per share, in Q2 2012. According to the Company, the decrease in net loss during the quarter was due to $11.5 million in revenue recorded by the Company in relation to a one-time payment for the sale of Insmed's right to receive future royalties under its license agreement with Premacure AB. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9c5b_INSM]

ImmunoGen, Inc. Research Report

On August 27, 2013, ImmunoGen, Inc. (ImmunoGen) announced that its Executive Vice President and CFO, Gregory D. Perry, has notified his intention to resign from the Company, effective September 13, 2013, to pursue other interests. According to ImmunoGen, it has initiated a search for Perry's replacement, while Daniel M. Junius, President and CEO will act as an interim CFO. Daniel M. Junius, said, "I sincerely appreciate Greg's service to ImmunoGen over the four years we have worked together. On behalf of the Company, I thank Greg for his many contributions and wish him well in his future endeavors." The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

VIVUS, Inc. Research Report

On August 27, 2013, VIVUS, Inc. (VIVUS) announced the online publication of a review article in Postgraduate Medicine, titled, "Treatment of Obesity in Primary Care: Targeting and Meeting Goals and Expectations (narrative review)." According to the Company, the manuscript discusses the treatment of obesity in the primary-care setting, and presents available medical treatment options, including Qsymia capsules CIV, to assist clinicians in addressing the medical needs of their parents who are overweight or obese. The Company further reported that the article emphasizes on the need for primary-care provider not only to manage the common comorbidities related to obesity, but also to recognize obesity as a physical and physiologic state, which requires effective therapy and ongoing management. The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8ae9_VVUS]

Theravance, Inc. Research Report

On August 14, 2013, Theravance, Inc. (Theravance) announced the commencement of VIBATIV (televancin) shipments into the US wholesaler channel. The Company informed that VIBATIV, discovered and developed by Theravance, is approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as for the treatment of complicated skin and skin structure infections (cSSSI). "VIBATIV is an important treatment option for physicians and patients dealing with serious MRSA infections," said Rick E. Winningham, CEO of Theravance. "Theravance intends to provide a level of medical support with this product reintroduction to enable physicians to properly use VIBATIV while we continue to evaluate commercialization alternatives in the U.S." The Full Research Report on Theravance, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fa70_THRX]

XOMA Corporation Research Report

On August 7, 2013, XOMA Corporation (XOMA) reported its Q2 2013 financial results. In Q2 2013, the Company's total revenues were $7.2 million, down 22.9% YoY, which reflected a reduction in license and collaborative fees. The Company reported Q2 2013 net loss of $17.2 million, or $0.21 per share, compared with a net loss of $16.2 million, or $0.24 per share, in Q2 2012. For full-year 2013, XOMA reconfirmed its anticipation that cash worth c.$50 million will be used in the ongoing operating activities during 2013, reflecting the costs associated with conducting clinical and preclinical activities. The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9a56_XOMA]

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

www.AnalystsCorner.com

SOURCE Analysts' Corner